PE20151663A1 - Composiciones de principios activos farmaceuticos que contienen monoetil eter dietilenglicol u otros derivados de alquilo - Google Patents

Composiciones de principios activos farmaceuticos que contienen monoetil eter dietilenglicol u otros derivados de alquilo

Info

Publication number
PE20151663A1
PE20151663A1 PE2015002110A PE2015002110A PE20151663A1 PE 20151663 A1 PE20151663 A1 PE 20151663A1 PE 2015002110 A PE2015002110 A PE 2015002110A PE 2015002110 A PE2015002110 A PE 2015002110A PE 20151663 A1 PE20151663 A1 PE 20151663A1
Authority
PE
Peru
Prior art keywords
diethylene glycol
monoethyl ether
alkyl derivatives
pharmaceutical compositions
compositions
Prior art date
Application number
PE2015002110A
Other languages
English (en)
Inventor
Dinesh Shantilal Patel
Sachin Dinesh Patel
Shashikant Prabhudas Kurani
Madhavlal Glovindlal Patel
Original Assignee
Themis Medicare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51263451&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20151663(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Themis Medicare Ltd filed Critical Themis Medicare Ltd
Publication of PE20151663A1 publication Critical patent/PE20151663A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invencion se relaciona con composiciones farmaceuticas de diversos principios activos farmaceuticos, especialmente principios activos hidrofilos y lipofilos que contienen monoetil eter dietilenglicol u otros derivados de alquilo de los mismos como un vehiculo primario y/o con composiciones farmaceuticas que utilizan monoetil eter dietilenglicol u otros derivados de alquilo de los mismos como un vehiculo primario o como un sistema de disolvente en la preparacion de dichas composiciones farmaceuticas. Las composiciones farmaceuticas de la presente invencion son seguras, no toxicas, exhiben estabilidad fisica mejorada comparado con formulaciones convencionales que contienen dichos principios activos farmaceuticos y son adecuadas para uso como inyectables para administracion intravenosa e intramuscular, asi como tambien para uso como una solucion/liquido preformado para relleno en y preparacion de capsulas, comprimidos, aerosoles nasales, sustancias para hacer gargaras, aplicaciones dermicas, genes, formas de dosificacion oral liquidas topicas y otras formas de dosificacion
PE2015002110A 2013-04-02 2014-04-02 Composiciones de principios activos farmaceuticos que contienen monoetil eter dietilenglicol u otros derivados de alquilo PE20151663A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN1287MU2013 IN2013MU01287A (es) 2013-04-02 2014-04-02

Publications (1)

Publication Number Publication Date
PE20151663A1 true PE20151663A1 (es) 2015-12-03

Family

ID=51263451

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015002110A PE20151663A1 (es) 2013-04-02 2014-04-02 Composiciones de principios activos farmaceuticos que contienen monoetil eter dietilenglicol u otros derivados de alquilo

Country Status (17)

Country Link
US (2) US9827315B2 (es)
JP (1) JP6272454B2 (es)
KR (2) KR101875263B1 (es)
CN (1) CN105392469A (es)
AU (1) AU2014261009B2 (es)
BR (1) BR112015025172A2 (es)
CA (1) CA2908571C (es)
HK (1) HK1222549A1 (es)
IN (1) IN2013MU01287A (es)
MA (1) MA38544A1 (es)
MX (1) MX2015013785A (es)
PE (1) PE20151663A1 (es)
PH (1) PH12015502290B1 (es)
SA (1) SA515361262B1 (es)
SG (1) SG11201508006SA (es)
UA (1) UA119324C2 (es)
WO (1) WO2014178065A1 (es)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120225918A1 (en) 2011-03-03 2012-09-06 Voom, Llc Compositions and Methods for Non-Surgical Treatment of Ptosis
US9713621B2 (en) * 2012-01-19 2017-07-25 Edward Lichten Treatment of endometriosis
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
KR102140989B1 (ko) 2012-05-03 2020-08-04 칼라 파마슈티컬스, 인크. 개선된 점막 수송을 나타내는 제약 나노입자
ES3055223T3 (en) 2012-05-03 2026-02-10 Alcon Inc Pharmaceutical nanoparticles showing improved mucosal transport
US9125805B2 (en) 2012-06-27 2015-09-08 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of small molecule drugs
US8568747B1 (en) 2012-10-05 2013-10-29 Silvergate Pharmaceuticals, Inc. Enalapril compositions
CN104546775B (zh) * 2015-02-03 2017-08-25 山东新时代药业有限公司 一种阿托伐他汀钙片剂
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
WO2017002030A1 (en) * 2015-06-30 2017-01-05 Leiutis Pharmaceuticals Pvt Ltd Stable liquid formulations of melphalan
JP2018530597A (ja) * 2015-10-13 2018-10-18 テミス メディケア リミティド フルベストラント組成物
KR101634382B1 (ko) * 2015-10-20 2016-06-28 미래제약 주식회사 타다라필 경구용 액제
US9463183B1 (en) * 2015-10-30 2016-10-11 Silvergate Pharmaceuticals, Inc. Lisinopril formulations
WO2017077425A1 (en) * 2015-11-07 2017-05-11 Ftf Pharma Private Limited Oral solution of ace inhibitors
EP3407875A4 (en) * 2016-01-29 2019-09-04 Cuda Anesthetics, LLC AQUEOUS PHARMACEUTICAL FORMULATION WITH PROPOFOL
US9669008B1 (en) 2016-03-18 2017-06-06 Silvergate Pharmaceuticals, Inc. Enalapril formulations
BR112018070960A2 (pt) * 2016-04-13 2019-01-29 Nortic Holdings Inc. formulação parenteral de nimodipina estável
US10092553B2 (en) 2016-04-13 2018-10-09 Nortic Holdings Inc. Stable nimodipine parenteral formulation
AU2017260327B2 (en) * 2016-05-06 2018-12-20 Harrow Ip, Llc Pharmaceutical Ophthalmic compositions and methods for fabricating thereof
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
ES3037596T3 (en) * 2016-06-28 2025-10-03 Emergent Biodefense Operations Lansing Llc Formulations of brincidofovir
EP3509592A4 (en) 2016-09-09 2020-07-22 Cutispharma, Inc. SUSPENSIONS AND DILUENTS FOR METRONIDAZOLE AND BACLOFEN
FR3057775B1 (fr) * 2016-10-26 2018-11-02 Crossject Solution pharmaceutique d’hydrocortisone pour dispositif d’injection
BE1024559B1 (nl) * 2017-02-21 2018-04-05 Purna Pharmaceuticals Nv Werkwijze voor het maken van een verstuifbare emulsie omvattende een corticosteroïde, een aminoglycoside en een zuur
CN108721209A (zh) * 2017-04-20 2018-11-02 广东东阳光药业有限公司 一种兽用阿奇霉素注射剂
ES2982668T3 (es) * 2017-06-02 2024-10-17 Xeris Pharmaceuticals Inc Formulaciones de fármacos de moléculas pequeñas resistentes a la precipitación
US9895359B1 (en) 2017-06-07 2018-02-20 Arcutis, Inc. Inhibition of crystal growth of roflumilast
US11129818B2 (en) 2017-06-07 2021-09-28 Arcutis Biotherapeutics, Inc. Topical roflumilast formulation having improved delivery and plasma half life
US20210161870A1 (en) 2017-06-07 2021-06-03 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
US12011437B1 (en) 2017-06-07 2024-06-18 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
US20200155524A1 (en) 2018-11-16 2020-05-21 Arcutis, Inc. Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
US12042487B2 (en) 2018-11-16 2024-07-23 Arcutis Biotherapeutics, Inc. Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
ES2984268T3 (es) * 2017-08-09 2024-10-29 Dechra Veterinary Products Llc Formulaciones terapéuticas que comprenden un inhibidor de la COX-2 y usos de las mismas
US11534493B2 (en) * 2017-09-22 2022-12-27 Arcutis Biotherapeutics, Inc. Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solvents
US10369134B2 (en) 2017-12-05 2019-08-06 Sunovion Pharmaceuticals Inc. Nonracemic mixtures and uses thereof
MX2020005517A (es) 2017-12-05 2020-11-09 Sunovion Pharmaceuticals Inc Formas cristalinas y metodos de produccion de las mismas.
WO2019182745A1 (en) * 2018-03-19 2019-09-26 Bryn Pharma, LLC Epinephrine spray formulations
CN110314158A (zh) * 2018-03-22 2019-10-11 深圳澳美制药技术开发有限公司 噻康唑组合物及其制备方法
US10799138B2 (en) 2018-04-05 2020-10-13 University Of Maryland, Baltimore Method of administering sotalol IV/switch
JP7492918B2 (ja) 2018-06-04 2024-05-30 アーキュティス・バイオセラピューティクス・インコーポレーテッド ロフルミラスト皮膚浸透ラグタイムを改善する方法及び配合物
US11696902B2 (en) 2018-08-14 2023-07-11 AltaThera Pharmaceuticals, LLC Method of initiating and escalating sotalol hydrochloride dosing
US11344518B2 (en) 2018-08-14 2022-05-31 AltaThera Pharmaceuticals LLC Method of converting atrial fibrillation to normal sinus rhythm and loading oral sotalol in a shortened time frame
US12396970B2 (en) 2021-08-20 2025-08-26 AltaThera Pharmaceuticals LLC Anti-arrhythmic compositions and methods
US11610660B1 (en) 2021-08-20 2023-03-21 AltaThera Pharmaceuticals LLC Antiarrhythmic drug dosing methods, medical devices, and systems
US10512620B1 (en) 2018-08-14 2019-12-24 AltaThera Pharmaceuticals, LLC Method of initiating and escalating sotalol hydrochloride dosing
CN109364021A (zh) * 2018-10-26 2019-02-22 山西普德药业有限公司 一种注射用长春西汀
US10814001B1 (en) 2019-05-06 2020-10-27 Rvl Pharmaceuticals, Inc. Oxymetazoline compositions
WO2020247627A1 (en) 2019-06-04 2020-12-10 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof
EP3982927A1 (en) 2019-06-14 2022-04-20 Propella Therapeutics, Inc. Topical acyclovir formulations and uses thereof
CN112138250B (zh) * 2019-06-28 2023-04-14 四川普锐特药业有限公司 保持给药均一度的药物流体分配器及右美托咪定鼻喷器
US11135208B2 (en) * 2019-08-12 2021-10-05 American Regent, Inc. 1,4-dihydropyridine compositions, methods of making and use
EP4233854A3 (en) * 2019-11-01 2024-01-17 Piedmont Animal Health Inc. Therapeutic formulations and uses thereof
MX2022007392A (es) * 2019-12-16 2022-07-27 Themis Medicare Ltd Composicion farmaceutica de inhibidores de la ciclooxigenasa 2.
CN111632029B (zh) * 2020-06-28 2021-05-07 江苏吴中医药集团有限公司 一种美索巴莫注射液及其制备方法
CA3192530A1 (en) * 2020-09-21 2022-03-24 Xiaoming Chen Aqueous pharmaceutical formulation of hydrocortisone sodium phosphate and monothioglycerol
EP4255393B1 (en) 2020-12-04 2025-05-28 Arcutis Biotherapeutics, Inc. Topical roflumilast formulation having antifungal properties
CN112315905B (zh) * 2020-12-07 2021-11-30 安徽海洋药业有限公司 一种蒿甲醚注射液及其制备方法
CN112370422B (zh) * 2020-12-09 2023-03-03 南京联智医药科技有限公司 取代的β-环糊精稳定的盐酸屈他维林注射液及其制备方法
US11452690B1 (en) 2021-01-27 2022-09-27 ECI Pharmaceuticals, LLC Oral liquid compositions comprising amlodipine besylate and methods of using the same
CN113004301B (zh) * 2021-03-11 2022-02-18 广西师范大学 一种青蒿琥酯基-二苯基脲衍生物ars-dpu及其制备方法与应用
CN113069527B (zh) * 2021-04-20 2022-03-18 北京华睿鼎信科技有限公司 一种具有解酒保肝功能的组合物及其制备方法
CN115252801B (zh) * 2021-04-29 2025-07-08 苏州裕泰医药科技有限公司 多西他赛-油酸甘油三酯前药及脂质制剂的制备
CN115702936A (zh) * 2021-08-13 2023-02-17 杭州中美华东制药有限公司 一种芦可替尼组合物及其用途
FR3128874B1 (fr) * 2021-11-09 2025-04-18 Crossject Solution pharmaceutique d’hydrocortisone pour dispositif d’injection
CA3242322A1 (en) 2021-12-28 2023-07-06 Arcutis Biotherapeutics, Inc. Topical roflumilast aerosol foams
EP4233837A1 (en) * 2022-02-24 2023-08-30 CellAct Pharma GmbH Solid and oral etoposide toniribate compositions
CN119300828A (zh) 2022-05-16 2025-01-10 美国阿卡斯蒂制药股份有限公司 尼莫地平肠胃外给药
AU2023342481A1 (en) 2022-09-15 2025-04-10 Arcutis Biotherapeutics, Inc. Pharmaceutical compositions of roflumilast and solvents capable of dissolving high amounts of the drug
KR20240105964A (ko) * 2022-12-29 2024-07-08 주식회사 삼양홀딩스 약동학적 특성이 우수한 풀베스트란트의 약학 조성물 및 그 제조 방법
CN121013718A (zh) * 2023-02-03 2025-11-25 美国倍利年制药有限公司 氨氯地平冻干组合物及其用途
WO2025041069A1 (en) * 2023-08-23 2025-02-27 Reena Patel Stabilized pharmaceutical compositions of proton pump inhibitors
US20250114388A1 (en) * 2023-10-09 2025-04-10 Dr. Anti Fungus, LLC Active pharmaceutical ingredient compositions and preparation and uses thereof
WO2025078989A1 (en) * 2023-10-11 2025-04-17 Reena Patel Stabilized pharmaceutical compositions
KR20250142811A (ko) * 2024-03-22 2025-09-30 주식회사 에아스텍 노르에티스테론 에난테이트 화합물의 암의 예방 또는 치료 용도
WO2025259038A1 (en) * 2024-06-13 2025-12-18 Chong Kun Dang Pharmaceutical Corp. Injectable composition comprising tadalafil or pharmaceutically acceptable salts thereof
CN118743693A (zh) * 2024-06-25 2024-10-08 杭州成邦医药科技有限公司 一种雷美替胺透皮贴剂及其制备方法
CN119269809B (zh) * 2024-11-27 2025-09-12 南京颐兰贝生物科技有限责任公司 一种用于定量检测雌二醇测定试剂盒
CN119499177A (zh) * 2024-11-28 2025-02-25 江苏知原药业股份有限公司 一种含有非挥发性溶剂的过氧化苯甲酰外用组合物
CN121287617A (zh) * 2025-12-10 2026-01-09 博济医药科技股份有限公司 一种氟康唑滴耳液及其制备方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030157187A1 (en) * 1996-12-02 2003-08-21 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating or preventing inflammatory diseases
FR2756736B1 (fr) * 1996-12-05 1999-03-05 Sanofi Sa Compositions pharmaceutiques contenant des derives de n-sulfonyl indoline
US20030104048A1 (en) * 1999-02-26 2003-06-05 Lipocine, Inc. Pharmaceutical dosage forms for highly hydrophilic materials
KR100382347B1 (ko) * 2000-10-30 2003-05-01 에스케이케미칼주식회사 시트상 자기발열체 및 이의 제조방법
IL142037A0 (en) * 2001-03-15 2002-03-10 Agis Ind 1983 Ltd Pharmaceutical compositions containing a non-steroidal anti-inflammatory drug
US6551615B1 (en) 2001-10-18 2003-04-22 M/S. Strides Arcolab Limited Dexibuprofen-containing soft gelatin capsules and process for preparing the same
AU2002357012A1 (en) * 2001-11-27 2003-06-10 Transform Pharmaceuticals, Inc. Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof
CA2486280A1 (en) * 2002-05-17 2004-04-01 New Horizons Diagnostics Corporation Identification of a phage associated lytic enzyme to rapidly and specifically detect and kill bacillus anthracis
US6967194B1 (en) * 2002-09-18 2005-11-22 Susan Matsuo Bio-identical hormones and method of use
JP4542743B2 (ja) * 2002-12-26 2010-09-15 Ｋｄｌ株式会社 ピリドン誘導体の溶液状医薬組成物
JP5017122B2 (ja) 2004-12-21 2012-09-05 インターベツト・インターナシヨナル・ベー・ベー 注射可能な獣医学組成物
EP1973557A4 (en) * 2005-12-13 2010-03-03 Harkness Pharmaceuticals Inc NON-HYGROSCOPIC COMPOSITIONS OF ENTEROSTATIN
US20110020440A1 (en) * 2007-11-19 2011-01-27 Cadila Pharmaceuticals Limited Stable solutions of sparingly soluble actives
US8128913B1 (en) * 2007-12-06 2012-03-06 Skinvisible Pharmaceuticals, Inc. Sunscreen composition with enhanced UV-A absorber stability and methods
HUP0700828A2 (en) * 2007-12-20 2010-01-28 Richter Gedeon Nyrt Transdermal pharmaceutical compositions containing tolperisone alone and in combination
WO2009128932A1 (en) * 2008-04-15 2009-10-22 Sarcode Corporation Delivery of lfa-1 antagonists to the gastrointestinal system
KR101096429B1 (ko) * 2008-07-18 2011-12-20 한국유나이티드제약 주식회사 안정성이 향상된 아세클로페낙의 경구용 연질캅셀제
US20100215726A1 (en) * 2009-02-25 2010-08-26 Peter Thomas Roth Compositions for Diminishing the Appearance of Wrinkles
US9744142B2 (en) * 2009-05-05 2017-08-29 Board Of Regents, The University Of Texas Systems Formulations of volatile anesthetics and methods of use for reducing inflammation
US9364485B2 (en) * 2009-08-31 2016-06-14 Dr. Reddy's Laboratories Ltd. Topical formulations comprising a steroid
US9737478B2 (en) * 2009-09-28 2017-08-22 National Institutes of Health (NIH), U.S. Dept. of Health and Human Services (DHHS), The United States of America NIH Division of Extramural Inventions and Technology Resources (DEITR) Treatment of malaria
CA2818891C (en) * 2009-11-27 2016-01-19 Nuvo Research Inc. Topical ibuprofen formulations
EP2575813A1 (en) * 2010-05-28 2013-04-10 Nuvo Research Inc. Topical etoricoxib formulation
US8747818B1 (en) * 2011-02-07 2014-06-10 Dennis Gross Self-tanning compositions
DK2704703T3 (da) * 2011-05-03 2019-10-14 Aponia Laboratories Inc Transdermale sammensætninger af ibuprofen og fremgangsmåder til anvendelse deraf
WO2014001904A1 (en) * 2012-06-27 2014-01-03 Medincell Biodegradable drug delivery for hydrophobic compositions

Also Published As

Publication number Publication date
SG11201508006SA (en) 2015-10-29
BR112015025172A2 (pt) 2017-07-18
CN105392469A (zh) 2016-03-09
CA2908571A1 (en) 2014-11-06
PH12015502290A1 (en) 2016-02-01
AU2014261009A1 (en) 2015-10-29
MA38544A1 (fr) 2017-03-31
KR101875263B1 (ko) 2018-07-05
HK1222549A1 (zh) 2017-07-07
US10940205B2 (en) 2021-03-09
IN2013MU01287A (es) 2015-05-29
JP6272454B2 (ja) 2018-01-31
PH12015502290B1 (en) 2016-02-01
US20140296191A1 (en) 2014-10-02
US20180071390A1 (en) 2018-03-15
MX2015013785A (es) 2016-08-19
CA2908571C (en) 2018-11-06
UA119324C2 (uk) 2019-06-10
KR20170110728A (ko) 2017-10-11
US9827315B2 (en) 2017-11-28
JP2016515609A (ja) 2016-05-30
KR20150126067A (ko) 2015-11-10
WO2014178065A1 (en) 2014-11-06
SA515361262B1 (ar) 2018-08-18
AU2014261009B2 (en) 2017-05-04

Similar Documents

Publication Publication Date Title
PE20151663A1 (es) Composiciones de principios activos farmaceuticos que contienen monoetil eter dietilenglicol u otros derivados de alquilo
MX2018003096A (es) Composicion farmaceutica que contiene farmaco anionico, y metodo de preparacion para la misma.
NZ709958A (en) Enhanced stability of novel liquid compositions
ECSP088403A (es) Formulacion farmaceutica de absorción oral y su método de administracion
CO2019012814A2 (es) Composición farmacéutica líquida estable
DOP2015000005A (es) Derivados de estra 1,3,5(10), 16 tetraeno 3 sustituidos, métodos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos
AR091039A1 (es) Composiciones farmaceuticas topicas que comprenden terbinafina, uso y metodo de tratamiento
DOP2016000007A (es) Pirazolpiridinas sustituidas
PE20160850A1 (es) Sistema multiparticulado para administrar drogas
BR112016008994A2 (pt) Compostos de pirido[2,3-d]pirimidin-4-ona como inibidores de tanquirase
BR112015027436A8 (pt) composição tópica e veículo para administração de ingredientes farmaceuticamente ou cosmeticamente ativos
MX2015010486A (es) Composicion masticable para administracion oral y proceso para preparar la misma.
MX369778B (es) Potenciadores de solubilidad del agua a base de glucogeno.
RU2015137043A (ru) Жидкие ментол-содержащие композиции
PE20130782A1 (es) Composiciones farmaceuticas que consisten de paracetamol y el proceso para la preparacion del mismo
MX2021000769A (es) Composicion farmaceutica que contiene clomipramina y metodo de preparacion de la misma.
BR112015014180A2 (pt) composições de gel
UA107631C2 (uk) Фармацевтична композиція лікарського засобу седативної і спазмолітичної дії у формі м'яких желатинових капсул (варіанти)
MX359106B (es) Composicion farmaceutica inyectable de dexketoprofeno y tramadol.
MX2015008330A (es) Composiciones farmaceuticas veterinarias novedosas y un metodo para la produccion de las mismas.
ES2422563A1 (es) Composición farmacéutica inyectable de ibuprofeno y arginina, su procedimiento de preparación, forma de dosificación unitaria y utilización de la misma
CR20150411A (es) Composiciones farmacéuticas que contienen dexketoprofeno y tramadol
UY35329A (es) Composición farmacéutica para administración oral que comprende fexofenadina y proceso para preparar la misma.
MX2015011099A (es) Composiciones farmaceuticas de donepezilo que tienen un perfil de disolución in vitro o parámetros farmacocinéticos específicos.
UA111358C2 (uk) Тверда лікарська форма препарату седативної та снодійної дії

Legal Events

Date Code Title Description
FD Application declared void or lapsed